Literature DB >> 15788645

Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.

Josien K Oosterhoff1, J Anton Grootegoed, Leen J Blok.   

Abstract

Prostate cancer development often includes a shift from androgen-dependent to androgen-independent growth. It is hypothesized that, during this transition, growth factors like the epidermal growth factor (EGF) gain importance as activators of tumour cell proliferation. To study this, androgen- and EGF-regulation of growth and gene-expression was analysed in the androgen-dependent human prostate cancer cell line LNCaP-FGC (FGC) and its androgen-independent derivative line LNCaP-LNO (LNO). It was observed that androgen-dependent FGC cells require exposure to either androgens or EGF to proliferate. This is in contrast to androgen-independent LNO cells that showed significant proliferation in medium depleted of androgens and growth factors. Gene expression data were obtained for the androgen-dependent FGC and androgen-independent LNO cells cultured in the presence or absence of androgens (synthetic R1881) or EGF for different time periods. Expression profiling showed that many cell cycle genes, including a number of androgen- and EGF-regulated genes, are constitutively activated in androgen-independent LNO cells. Furthermore, the overlap between changes in gene expression activated by androgen and EGF receptor signalling pathways was found to be very high (75%). These results partly explain why androgen-independent LNO cells can proliferate in the absence of androgenic stimulation. However, possibly other, so far unknown, signal transduction pathways that induce and maintain proliferation, have also been activated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788645     DOI: 10.1677/erc.1.00897

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  APRIN is a unique Pds5 paralog with features of a chromatin regulator in hormonal differentiation.

Authors:  Maricel Maffini; Viktoria Denes; Carlos Sonnenschein; Ana Soto; Peter Geck
Journal:  J Steroid Biochem Mol Biol       Date:  2007-09-12       Impact factor: 4.292

2.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Authors:  Meng-Lei Zhu; Craig M Horbinski; Mark Garzotto; David Z Qian; Tomasz M Beer; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

3.  "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response.

Authors:  Adaikkalam Vellaichamy; Zoltán Dezso; Lellean JeBailey; Arul M Chinnaiyan; Arun Sreekumar; Alexey I Nesvizhskii; Gilbert S Omenn; Andrej Bugrim
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

4.  LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Authors:  Tammy L Romanuik; Gang Wang; Olena Morozova; Allen Delaney; Marco A Marra; Marianne D Sadar
Journal:  BMC Med Genomics       Date:  2010-09-24       Impact factor: 3.063

Review 5.  Stroma-epithelium crosstalk in prostate cancer.

Authors:  Yi-Nong Niu; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

6.  Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.

Authors:  Inge Seim; Penny L Jeffery; Patrick B Thomas; Colleen C Nelson; Lisa K Chopin
Journal:  G3 (Bethesda)       Date:  2017-06-07       Impact factor: 3.154

7.  Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression.

Authors:  Kandice L Tessneer; Satish Pasula; Xiaofeng Cai; Yunzhou Dong; Xiaolei Liu; Lili Yu; Scott Hahn; John McManus; Yiyuan Chen; Baojun Chang; Hong Chen
Journal:  ISRN Oncol       Date:  2013-04-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.